

Fig. 1

	Peptide	Peptide conc. (μM)	Mean viability	Mean % of PMO+ cells	Mean Delivery Score	Delivery-Viability Score	Peptide sequence	SEQ ID NO:
Controls	Cargo alone	-	100%	0%	0.00	0.1	-	-
	FSD10 scramble	7.5	108%	0%	0.01	0.0	FRAKALKRGKSWKGGSYALARRQRAALTGGAI	51
Domain-based shuttle agents	His-LAH4-PTD4	7.5	100%	4%	0.06	0.6	HHHHKKKALLALALHHLHLALHLALAKKAYARAAARQARA	4
	TAT-KALA	7.5	69%	6%	0.12	0.8	YGRKKRRQRRRWEAKLAKALAKALAKHLAKALAKACEA	2
	PTD4-KALA	7.5	108%	8%	0.15	1.6	YARAAARQARAWAEAKLAKALAKALAKHLAKALAKACEA	5
	EB1-PTD4	7.5	81%	20%	0.62	5.0	LIRLWSHLIHWFQNRRLKWKKKYARAAARQARA	6
	FSD134	7.5	77%	51%	1.34	10.3	LIRKWIHLIHWFQNLRLYARAAARQARA	23
	FSD336	7.5	90%	27%	1.31	11.8	KWKLRLFLRIFPKLGGSGGSQARARQAR	246
Rationally-design shuttle agents	FSD301	10	91%	42%	1.50	13.6	GGSGGSKWKLKLWSRLKLWGGSGGS	212
	FSD5	7.5	84%	49%	2.53	21.3	HHHHHLLKLWSRLKLWTOGRRLKAKRAHHHHH	12
	FSD367	20	91%	40%	2.40	21.9	KWKLKLWSRLKLGGQAR	277
	FSD201	20	101%	48%	2.30	23.4	WSRLIKLWTOGRRLKARAA	127
	FSD21	7.5	84%	48%	2.81	23.6	HHHHHFLKIWSRLIKIWTQGRKGAQAFR	17
	FSD210	7.5	85%	64%	3.51	29.7	KWKLARAFARAIKKGSGGSRRLKAKRAKA	136
	FSD231	7.5	50%	75%	6.53	32.5	KWKLARAFARAIKKGSGGSRRLKAKRALKA	156
	FSD19	7.5	94%	60%	3.45	32.5	HHHHHLLKLWSRLKLWTOGRRLKAKSAQASTQAHHHHH	16
	FSD162	7.5	57%	73%	6.29	35.6	ILKLWSRLIKIWTQGRKKAQAAKR	29
	FSD10	7.5	93%	76%	3.93	36.7	KWKLARAFARAIKKGSGGSGSYARALRRQARTG	13
	FSD174	7.5	80%	68%	5.28	42.0	LLKIWSRLIKIWTQGRRLGGSGGSARAAARQAR	32
	FSD396	7.5	93%	55%	4.52	42.2	KLKLAKLLKALKLGGSGGSGQAQAKQAK	305
	FSD18	7.5	67%	73%	6.71	45.2	LLKLWSRLKLWTOGGSGGSRRLKAKRAKA	15
	FSD250	7.5	68%	82%	6.79	46.1	KWKLKLWSRLKLWGGSGGSARAAARQAR	35

Fig. 2

	Cargo	Cargo conc.	Mean viability	Mean % GFP+ cells (5h post-transduction)
No treatment	-	-	100%	65%
Cargo alone	PMO-GFP	0.1 μ M 10 μ M	79% 110%	66% 66%
	PMO-Gli1	0.1 μ M 10 μ M	88% 82%	65% 66%
FSD10 (7.5 μ M)	PMO-GFP	0.1 μ M 10 μ M	83% 51%	61% 34%
	PMO-Gli1	0.1 μ M 10 μ M	70% 56%	66% 69%
	-	-	74%	65%
	siRNA-GFP	50 nM	126%	14%*
Lipofectamine [®] RNAiMax	siRNA-Gli1	50 nM	98%	52%*

* Measured 48 hours post-transfection based on manufacturer's instructions.

Fig. 3




Fig. 4




Fig. 5

SEQ ID NO	Candidate shuttle agent (10 μ M)	Propidium iodide (10 μ g/mL)			GFP-NLS (10 μ M)		
		Mean Viability	Norm. Mean Delivery Score ¹	Mean % of PI+ cells	Mean Viability	Norm. Mean Delivery Score ¹	Mean % of GFP+ cells
1	CM18-Penetratin-cys	52%	12.1	12%	58%	25.5	18%
2	TAT-KALA	105%	8.4	12%	102%	4.6	9%
3	His-CM18-PTD4	66%	21.3	19%	71%	61.2	25%
4	His-LAH4-PTD4	109%	11.4	13%	102%	7	12%
5	PTD4-KALA	103%	7.8	10%	105%	29.9	22%
6	EB1-PTD4	70%	48.6	38%	77%	87.8	47%
12	FSD5	63%	39.2	37%	65%	57.2	30%
13	FSD10	100%	13.9	67%	104%	119.7	72%
15	FSD18	70%	65.2	30%	77%	129.2	42%
16	FSD19	89%	65.4	38%	96%	92	44%
17	FSD21	95%	43.3	35%	87%	87.8	41%
19	FSD120	80%	46.4	43%	109%	119.5	42%
21	FSD129	96%	69.8	40%	89%	195.6	49%
21	FSD129	104%	13.4	47%	117%	61.2	43%
22	FSD131	85%	35.5	43%	100%	92	42%
23	FSD134	83%	53.9	44%	83%	126.3	64%
23	FSD134	66%	11.8	55%	64%	154.7	65%
24	FSD146	98%	97.4	61%	98%	220.2	58%
26	FSD156	40%	53.8	30%	44%	107.7	36%
26	FSD156	31%	14.5	49%	55%	80	42%
27	FSD157	30%	98.9	58%	76%	285.2	57%
28	FSD159	80%	77.6	54%	56%	233	53%
29	FSD162	61%	85.2	54%	92%	344.2	66%
30	FSD168	88%	61.5	55%	86%	269.6	53%
31	FSD173	109%	27.8	30%	95%	232.4	63%
32	FSD174	93%	74.9	35%	85%	246.5	51%
33	FSD194	77%	22.6	37%	62%	292.4	78%
34	FSD220	102%	54.6	28%	102%	232.9	49%
35	FSD250	119%	33.6	37%	114%	284.8	70%
36	FSD250D	100%	5.4	14%	91%	12.9	19%
37	FSD253	73%	98.3	65%	65%	185.8	73%
38	FSD258	76%	106.2	69%	113%	178.6	62%
39	FSD262	81%	75.6	65%	88%	376.1	77%
40	FSD263	81%	88.7	68%	100%	279.3	75%
42	FSD265	86%	102	72%	80%	404.9	82%
43	FSD268	96%	52.1	33%	106%	131	51%
44	FSD286	87%	74.2	52%	90%	165.5	61%
45	FSD271	77%	73.8	63%	89%	279.5	73%
46	FSD272	85%	99.3	71%	97%	332.5	78%
47	FSD273	88%	91.9	66%	98%	321	74%
49	FSD268 Cyclic Amide	97%	52.1	29%	87%	155.4	50%

Fig. 5 (cont'd)

SEQ ID NO	Candidate shuttle agent (10 μ M)	Propidium iodide (10 μ g/mL)			GFP-NLS (10 μ M)		
		Mean Viability	Norm. Mean Delivery Score ¹	Mean % of PI+ cells	Mean Viability	Norm. Mean Delivery Score ¹	Mean % of GFP+ cells
50	FSD268 Cyclic Disulfide	91%	30.1	21%	88%	119	48%
58	FSD117	99%	5.8	33%	122%	46.3	42%
59	FSD118	96%	12.9	41%	104%	73.6	45%
60	FSD119	71%	7	30%	109%	36.4	29%
61	FSD121	81%	19	46%	104%	76.2	44%
62	FSD122	80%	14.5	42%	99%	76	47%
63	FSD123	85%	13.5	32%	96%	86	36%
64	FSD124	88%	15.3	46%	98%	79.8	51%
65	FSD125	91%	14.3	46%	104%	87.6	51%
66	FSD126	93%	1.6	13%	107%	7.9	14%
67	FSD127	98%	3.5	22%	94%	16.6	16%
68	FSD128	97%	10.6	39%	87%	31.7	33%
69	FSD130	94%	2.5	16%	114%	25.1	40%
70	FSD132	80%	2.9	21%	110%	8.2	17%
71	FSD133	90%	10.4	37%	122%	56.2	46%
72	FSD135	105%	48.4	62%	99%	103.2	52%
73	FSD137	81%	1.5	10%	113%	0.7	7%*
74	FSD239	81%	9.7	40%	121%	41.1	44%
75	FSD139	82%	7.7	35%	97%	4	11%
76	FSD140	81%	6.9	31%	96%	13.1	19%
77	FSD141	91%	9.8	34%	95%	15.2	27%
78	FSD142	75%	4.3	26%	110%	4.9	10%*
80	FSD144	96%	1	10%	108%	3.8	11%
81	FSD145	103%	2.8	27%	107%	2.6	7%*
82	FSD147	84%	7.6	39%	90%	119.2	70%
83	FSD148	80%	1.1	11%	113%	5.4	5%
84	FSD149	70%	3.9	23%	107%	31	29%
85	FSD150	82%	17.4	49%	109%	88.3	54%
86	FSD151	79%	9.9	38%	105%	47.4	32%
87	FSD152	73%	13.7	45%	98%	69.6	41%
88	FSD153	41%	13.7	44%	89%	96.7	51%
89	FSD154	79%	18.7	49%	102%	44.5	30%
90	FSD158	57%	14.6	56%	43%	51.7	37%
91	FSD160	69%	14	38%	73%	147.9	53%
92	FSD161	78%	15.1	42%	102%	92.6	48%
93	FSD163	58%	16.8	47%	92%	115.5	59%
94	FSD164	24%	25.4	49%	101%	115.7	55%
95	FSD165	13%	18.3	51%	72%	95.3	55%
96	FSD166	61%	10.7	38%	29%	87.9	48%
97	FSD167	103%	5.9	29%	59%	81.4	45%
98	FSD169	105%	2.4	14%	89%	75.2	43%
99	FSD170	91%	15.4	35%	87%	166.4	61%
100	FSD171	108%	6.6	30%	107%	140.5	65%
101	FSD172	90%	4.6	20%	112%	87.3	47%

Fig. 5 (cont'd)

SEQ ID NO	Candidate shuttle agent (10 μ M)	Propidium iodide (10 μ g/mL)			GFP-NLS (10 μ M)		
		Mean Viability	Norm. Mean Delivery Score ¹	Mean % of PI+ cells	Mean Viability	Norm. Mean Delivery Score ¹	Mean % of GFP+ cells
102	FSD175	113%	8.8	29%	106%	152.5	58%
103	FSD176	80%	6.2	24%	99%	148.5	59%
104	FSD177	99%	1.9	11%	101%	44.6	47%
105	FSD178	95%	1.7	10%	105%	18.4	37%
106	FSD179	108%	5.6	29%	91%	77.1	53%
107	FSD180	92%	5.2	26%	57%	69.8	51%
109	FSD182	108%	1.8	11%	102%	2.5	10%
110	FSD183	85%	4.1	17%	102%	132	54%
111	FSD184	93%	11.1	28%	99%	154.3	62%
112	FSD185	82%	10.6	33%	73%	159.1	61%
113	FSD186	88%	2	12%	107%	83.1	51%
114	FSD187	97%	9.3	41%	78%	123.5	66%
115	FSD188	95%	3.1	16%	94%	76.1	56%
116	FSD189	100%	7.1	29%	86%	185.1	71%
117	FSD190	107%	3.7	18%	110%	81.2	45%
118	FSD191	93%	2.2	14%	114%	31	38%
119	FSD192	96%	4.4	22%	104%	69.5	46%
120	FSD193	82%	7.6	37%	51%	154.5	73%
121	FSD195	85%	13.9	45%	83%	177.6	69%
122	FSD196	98%	12.3	40%	60%	140.2	54%
123	FSD197	48%	10.8	39%	73%	174.5	69%
124	FSD198	93%	2.2	13%	106%	3	6%
125	FSD199	90%	15.5	60%	14%	28.7	25%
126	FSD200	88%	13.2	42%	48%	137.3	56%
127	FSD201	98%	2	12%	110%	5.7	13%
128	FSD202	82%	2.8	16%	114%	18.2	39%
129	FSD203	87%	1.9	11%	112%	2.5	9%
130	FSD204	79%	3.2	18%	111%	23.4	32%
131	FSD205	96%	2.6	15%	112%	0.4	1%
132	FSD206	89%	3.6	20%	96%	49.2	37%
133	FSD207	105%	2.6	17%	111%	16.2	28%
134	FSD208	95%	6.3	33%	99%	132.2	68%
135	FSD209	66%	4.9	27%	112%	77.2	61%
136	FSD210	57%	7.3	36%	93%	129.5	74%
137	FSD211	63%	5.9	29%	89%	122.7	66%
138	FSD212	92%	2.1	11%	95%	11	30%
139	FSD213	56%	16.4	41%	104%	161.2	62%
141	FSD215	71%	6.6	30%	107%	80.8	54%
142	FSD216	64%	11.7	43%	111%	97.1	60%
143	FSD217	61%	1.6	10%	115%	8	26%
144	FSD218	111%	3	17%	115%	8.6	35%
145	FSD219	131%	9	27%	109%	74.2	45%
146	FSD221	58%	6.1	26%	69%	71.5	46%
149	FSD224	62%	8.1	38%	81%	93.7	66%
150	FSD225	128%	12.4	43%	82%	122.5	62%

Fig. 5 (cont'd)

SEQ ID NO	Candidate shuttle agent (10 μ M)	Propidium iodide (10 μ g/mL)			GFP-NLS (10 μ M)		
		Mean Viability	Norm. Mean Delivery Score ¹	Mean % of PI+ cells	Mean Viability	Norm. Mean Delivery Score ¹	Mean % of GFP+ cells
151	FSD226	137%	9.3	39%	95%	85.8	61%
152	FSD227	60%	6.3	27%	91%	116.7	58%
153	FSD228	86%	6.3	32%	80%	118.7	67%
154	FSD229	88%	11	44%	79%	111.2	63%
155	FSD230	96%	13	56%	121%	72.5	61%
156	FSD231	80%	20.5	67%	99%	181.3	75%
157	FSD232	98%	18.2	71%	108%	76.2	69%
158	FSD233	75%	14.2	58%	122%	97.3	62%
159	FSD234	99%	7.5	38%	77%	48.7	31%
160	FSD235	95%	13.1	56%	104%	79.5	59%
161	FSD236	62%	2.7	20%	117%	14.3	23%
163	FSD238	89%	30.5	67%	107%	189.9	80%
164	FSD138	83%	22.9	40%	95%	66.9	64%
165	FSD240	93%	1.7	14%	116%	4.9	18%
166	FSD241	94%	9.4	43%	107%	119.3	60%
167	FSD243	77%	10.6	40%	114%	107.6	61%
168	FSD244	56%	20.5	60%	111%	128.5	69%
169	FSD246	58%	30.5	74%	91%	142.8	66%
171	FSD248	132%	12.3	46%	96%	148.3	56%
174	FSD251	93%	6.9	31%	85%	149.7	58%
175	FSD254	85%	10.8	38%	92%	111.3	49%
176	FSD255	85%	18.2	63%	105%	81.6	59%
177	FSD256	83%	3.8	25%	98%	26.1	41%
178	FSD257	89%	20.3	57%	103%	24.5	37%
179	FSD259	95%	26.1	65%	82%	141.1	67%
180	FSD260	89%	21.3	55%	88%	183	69%
181	FSD261	88%	17.1	46%	95%	168.3	60%
182	FSD266	92%	14.5	56%	95%	77.6	55%
183	FSD267	89%	6.7	39%	76%	44.1	38%
184	FSD269	89%	12	52%	68%	105.7	63%
185	FSD270	79%	16.6	54%	103%	172.4	72%
186	FSD274	76%	14.4	51%	91%	134.5	68%
187	FSD275	94%	16.9	55%	118%	30.3	42%
188	FSD276	109%	16.9	56%	100%	144.1	76%
189	FSD277	104%	47.1	70%	95%	188.3	72%
190	FSD278	101%	3.5	26%	103%	39.1	42%
191	FSD279	89%	6.3	34%	103%	17.6	31%
192	FSD280	100%	26	74%	104%	86.1	73%
193	FSD281	107%	54.6	68%	85%	201.7	76%
194	FSD282	116%	18.5	66%	86%	80.1	61%
195	FSD283	110%	3	28%	99%	5.7	27%
196	FSD284	116%	2.9	21%	95%	10.3	20%
197	FSD285	113%	3.3	26%	93%	4.9	19%
198	FSD287	105%	9.8	48%	90%	102.6	57%
199	FSD288	82%	19.9	67%	96%	89.2	72%

Fig. 5 (cont'd)

SEQ ID NO	Candidate shuttle agent (10 μ M)	Propidium iodide (10 μ g/mL)			GFP-NLS (10 μ M)		
		Mean Viability	Norm. Mean Delivery Score ¹	Mean % of PI+ cells	Mean Viability	Norm. Mean Delivery Score ¹	Mean % of GFP+ cells
200	FSD289	89%	39.8	82%	85%	131.1	75%
201	FSD290	101%	30.5	57%	69%	229.1	73%
202	FSD291	102%	44.6	84%	77%	234.4	85%
203	FSD292	101%	2	19%	98%	2.2	5%
204	FSD293	100%	13.3	43%	90%	8.9	18%
205	FSD294	81%	16.2	43%	86%	167.3	61%
206	FSD295	84%	18.8	43%	97%	40	34%
207	FSD296	40%	45.7	74%	84%	247.4	82%
208	FSD297	102%	42.1	72%	79%	247.2	81%
209	FSD298	101%	62.3	74%	90%	219.3	76%
210	FSD299	94%	3.8	30%	94%	16.5	32%
211	FSD300	89%	3.5	28%	108%	3.9	11%
212	FSD301	84%	24.2	48%	95%	87.8	51%
213	FSD302	89%	54.2	80%	94%	228.4	83%
214	FSD303	91%	50.2	77%	86%	198	77%
215	FSD304	83%	37.7	72%	96%	160.2	73%
216	FSD305	94%	50.1	78%	97%	254.5	86%
217	FSD306	81%	55.3	76%	96%	209.4	82%
218	FSD307	61%	26.1	60%	97%	107.6	62%
219	FSD308	85%	54	78%	85%	247.4	86%
220	FSD309	62%	25	56%	64%	221.5	69%
221	FSD310	90%	51.4	81%	92%	217.3	81%
222	FSD311	43%	47.6	80%	74%	211.3	79%
223	FSD312	90%	1.7	17%	98%	1.8	5%*
224	FSD313	66%	49.1	71%	57%	210.1	71%
225	FSD314	87%	36.1	70%	90%	119.8	69%
226	FSD315	93%	67.4	63%	89%	210.8	66%
227	FSD316	73%	36.5	69%	82%	202.2	74%
228	FSD317	58%	1.9	17%	107%	2.6	6%*
229	FSD318	65%	63.6	60%	74%	227.2	65%
230	FSD319	85%	43.3	73%	73%	250.6	75%
231	FSD320	109%	42.9	67%	76%	220.4	72%
232	FSD321	46%	13.9	32%	65%	156.5	53%
233	FSD322	55%	25.7	37%	132%	117.5	54%
234	FSD323	90%	27.9	54%	38%	90.7	53%
236	FSD325	56%	25.1	51%	141%	70.6	50%
237	FSD326	89%	1.7	10%	145%	9.5	27%
238	FSD327	98%	12.4	35%	95%	73.4	48%
239	FSD328	83%	14.1	33%	132%	81.9	53%
240	FSD330	87%	26.1	47%	124%	71.6	51%
242	FSD332	73%	2	13%	123%	0.9	5%
243	FSD333	39%	30.9	60%	69%	197.1	86%
244	FSD334	68%	12.8	47%	75%	87	80%
245	FSD335	37%	32.9	53%	76%	124.5	68%
246	FSD336	63%	42.4	78%	84%	164.5	90%

Fig. 5 (cont'd)

SEQ ID NO	Candidate shuttle agent (10 μ M)	Propidium iodide (10 μ g/mL)			GFP-NLS (10 μ M)		
		Mean Viability	Norm. Mean Delivery Score ¹	Mean % of PI+ cells	Mean Viability	Norm. Mean Delivery Score ¹	Mean % of GFP+ cells
247	FSD337	92%	57.8	76%	66%	186.2	87%
248	FSD338	52%	40.9	69%	65%	169.3	89%
249	FSD339	86%	23.2	55%	92%	95.6	65%
250	FSD340	51%	60	77%	85%	169.9	83%
251	FSD341	104%	29.4	59%	66%	106.8	65%
252	FSD342	83%	59.2	86%	37%	92.2	70%
253	FSD343	38%	8.6	31%	115%	25.7	38%
254	FSD344	31%	35	51%	99%	188.1	68%
255	FSD345	51%	50.8	69%	86%	181.2	78%
256	FSD346	84%	58.4	81%	70%	193.2	84%
257	FSD347	44%	55.1	77%	75%	130.6	74%
258	FSD348	76%	38.3	70%	108%	68.2	68%
259	FSD349	104%	64.3	84%	90%	202.4	82%
260	FSD350	70%	50.7	70%	111%	100.6	65%
262	FSD352	58%	57.8	69%	105%	154.9	71%
263	FSD353	66%	2.1	13%	123%	1.1	5%
264	FSD354	61%	45.7	62%	102%	123.5	64%
265	FSD355	62%	41.7	60%	98%	124.7	61%
266	FSD356	97%	33.9	60%	102%	147.8	71%
267	FSD357	36%	27.9	69%	108%	42.1	44%
268	FSD358	77%	26.2	50%	120%	94.3	59%
269	FSD359	74%	52.3	79%	83%	213.1	82%
270	FSD360	78%	98.5	84%	105%	89.4	75%
271	FSD361	67%	13.6	29%	95%	97.3	39%
272	FSD362	89%	22.2	44%	114%	53.6	38%
273	FSD363	89%	13.3	28%	104%	49.7	31%
274	FSD364	74%	5.3	21%	165%	6.7	17%
275	FSD365	77%	18.3	44%	152%	96.3	58%
276	FSD366	74%	9.1	28%	140%	89.8	44%
277	FSD367	69%	4.5	20%	150%	31.9	28%
278	FSD368	68%	14.3	40%	130%	139.4	58%
279	FSD369	75%	13.6	42%	161%	116.8	58%
280	FSD370	72%	18.2	58%	161%	80	61%
281	FSD371	72%	30.6	61%	139%	119.7	53%
282	FSD372	67%	13.3	49%	140%	63.9	53%
283	FSD373	77%	11	29%	144%	93.2	48%
284	FSD374	73%	16.3	35%	152%	111	49%
285	FSD375	57%	8.7	23%	150%	62.7	32%
287	FSD377	63%	10.7	30%	159%	36.6	34%
288	FSD378	65%	18.1	33%	144%	35.1	31%
289	FSD379	47%	10.1	33%	76%	87.9	54%
290	FSD381	72%	16.3	37%	66%	115.2	44%
291	FSD382	94%	11	31%	44%	93.5	45%
292	FSD383	74%	30.5	52%	21%	91.6	55%
293	FSD384	81%	2.4	13%	106%	15.3	23%

Fig. 5 (cont'd)

SEQ ID NO	Candidate shuttle agent (10 μ M)	Propidium iodide (10 μ g/mL)			GFP-NLS (10 μ M)		
		Mean Viability	Norm. Mean Delivery Score ¹	Mean % of PI+ cells	Mean Viability	Norm. Mean Delivery Score ¹	Mean % of GFP+ cells
294	FSD385	88%	37.5	62%	31%	105.5	60%
296	FSD387	58%	3.4	18%	94%	74.5	50%
297	FSD388	84%	22.5	56%	70%	56.9	54%
298	FSD389	83%	8	29%	50%	72.5	41%
299	FSD390	93%	3.7	19%	98%	38.5	45%
300	FSD391	81%	25.1	57%	55%	94.7	59%
302	FSD393	52%	24.3	58%	61%	59.5	54%
303	FSD394	69%	4.7	23%	23%	17	25%
304	FSD395	98%	34.1	67%	74%	303	87%
305	FSD396	79%	8.1	29%	85%	105.1	50%
306	FSD397	74%	1.6	11%	99%	10.4	30%
307	FSD398	88%	6.8	26%	87%	70.5	53%
308	FSD399	73%	7.9	27%	94%	66.3	49%
310	FSD401	99%	28.4	55%	93%	144.9	68%
311	FSD402	79%	20.6	34%	64%	108.2	41%
313	FSD404	72%	8.4	29%	85%	72	54%
314	FSD406	65%	28	64%	75%	174.7	74%
315	FSD407	110%	28.9	66%	62%	203.3	80%
316	FSD408	72%	14.6	45%	72%	102.1	58%
317	FSD409	82%	1.1	10%	89%	5.2	10%
318	FSD410	88%	3.1	19%	45%	14.5	20%
319	FSD411	110%	27.6	66%	65%	200.4	81%
320	FSD412	118%	10.9	40%	71%	63.9	47%
321	FSD413	45%	1.6	13%	82%	5.1	15%
322	FSD414	97%	2.8	19%	106%	14.8	26%
323	FSD415	110%	14.8	43%	78%	124	56%
324	FSD416	106%	8.2	28%	101%	48.1	32%
326	FSD418	107%	5.3	26%	91%	70.3	55%
327	FSD419	99%	1.7	13%	102%	8	19%
328	FSD421	103%	3.7	21%	106%	38.9	33%
329	FSD422	96%	4.1	22%	94%	8.1	31%
330	FSD423	79%	1	10%	106%	4	17%
331	FSD424	78%	7.7	24%	90%	75.5	37%
332	FSD425	126%	22.9	12%	94%	111.4	27%
338	FSD431	107%	98.9	26%	88%	407	50%
339	FSD432	110%	31.3	12%	87%	266.3	39%
340	FSD433	104%	45	26%	90%	247.5	54%
341	FSD434	108%	38.1	13%	82%	282.5	43%
342	FSD435	41%	119.5	47%	55%	339.1	67%
344	FSD438	59%	397.5	81%	69%	686.2	84%

¹ Normalized Mean Delivery Scores were normalized to that of the “cargo alone” control for each experimental batch.

Fig. 6

SEQ ID NO	Candidate shuttle agent (10 μ M)	Propidium iodide (10 μ g/mL)			GFP-NLS (10 μ M)		
		Mean Viability	Mean Delivery Score ¹	Mean % of PI+ cells	Mean Viability	Mean Delivery Score ¹	Mean % of GFP+ cells
-	Cargo only	84%	0.3	5%	101%	0.0	0%
351	PTD4	124%	0.2	4%	111%	0.0	0%
352	TAT	106%	0.1	1%	115%	0.0	2%
353	CM18	75%	4.4	29%	57%	1.3	18%
354	KALA	120%	2.3	25%	97%	0.2	8%
355	Penetratin	106%	1.4	18%	104%	1.5	47%
356	FSD92	129%	1.0	11%	80%	2.3	38%
357	FSD10-15	92%	2.4	15%	128%	1.3	45%
358	FSD418-12-2	91%	3.1	20%	70%	1.2	20%
359	FSD418-15	70%	1.4	14%	105%	0.3	10%
360	FSD440	47%	5.8	26%	98%	2.9	33%
361	FSD441	106%	1.8	20%	99%	0.7	22%
362	FSD443	249%	0.8	9%	99%	0.2	10%
363	FSD445	-	-	-	95%	3.9	41%
364	FSD446	-	-	-	100%	7.0	68%

Fig. 7A




Fig. 7B




Fig. 8A




Fig. 8B




Fig. 9A




Fig. 9B




Fig. 10A




Fig. 10B






Fig. 11A




Untreated cells

Fig. 11B




PMO-FITC alone

Fig. 11C



PMO-FITC + FSD396 (10 μ M, 5 mins)

Fig. 11D



PMO-FITC + Endoport (5 μ M, 48 h)

Fig. 12




Fig. 13

